OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

OptimizeRx reported third-quarter 2026 revenue of $21.6 million, a 17% decrease compared to $26.1 million in the same period of 2025. The company achieved GAAP net income of $1.2 million, or $0.06 per share. Management updated its fiscal year 2026 revenue guidance to a range of $87 million to $93 million, while maintaining its adjusted EBITDA guidance of $21 million to $25 million. The company also reported that it has repaid $9.3 million in debt principal since June 30, 2026, reducing its outstanding principal to $10.4 million. Leadership attributed the revenue outlook revision to in-year contracted revenue tracking below prior-year levels but expressed optimism regarding growth in 2027 contracted revenue and the upcoming RFP season.